Rentokil Initial


Positive momentum continues

12/08/19 -"The upward revision in the target price is backed by all valuation metrics. In the DCF, we have incorporated Rentokil’s sustained strong financial performance (so far in FY19, it has exceeded the ..."

Pages
44
Language
English
Published on
12/08/19
You may also be interested by these reports :
12/08/19
Over the past two years, SGS (Add, Switzerland)’s performance was not as stellar as we could have imagined for such a leading business surfing on ...

12/08/19
The upward revision in the target price is backed by all valuation metrics. In the DCF, we have incorporated Rentokil’s sustained strong financial ...

08/08/19
Randstad Holding has been trading against a tougher economic backdrop since H2 18. In H1 19, organic revenue decreased by 1% due to Europe (70% of ...

08/08/19
Adecco’s Q2 organic growth of -3% was slightly below the street’s expectation at -2.7%, while the EBITA excluding one-offs of €265m came in above ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO